Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)

Life Sciences

Volumn 91, Issue 13-14, 2012, Pages 739-742

  Andress, Dennis L ^a   Coll, Blai ^a   Pritchett, Yili ^a   Brennan, John ^a   Molitch, Mark ^b   Kohan, Donald E ^c  

^a ABBOTT LABORATORIES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Albuminuria; Atrasentan; Chronic kidney disease; Diabetes; Diabetic nephropathy; Endothelin

Indexed keywords

ALBUMIN; ATRASENTAN; CREATININE; DIURETIC AGENT; PLACEBO;

ADULT; AGED; ALBUMINURIA; ANGIONEUROTIC EDEMA; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

AGED; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; GLOMERULAR FILTRATION RATE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84867418316     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.01.011     Document Type: Conference Paper

References (15)

1. D. Bolignano, A. Lacquaniti, G. Coppolino, V. Donato, S. Campo, and M. Fazio Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease Clin J Am Soc Nephrol 4 2 2009 337 344
2. J.C. Chan, N.M. Wat, W-Y. So, K. Lam, C-T. Chua, and K-S. Wong Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study Diabetes Care 27 4 2004 874 879
3. N. Dhaun, I.M. MacIntyre, D. Kerr, V. Melville, N. Johnston, and S. Haughie Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease Hypertension 57 4 2011 772 779
4. E. Gagliardini, D. Corna, C Zoja, F. Sangalli, F. Carrara, and M. Rossi Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol 297 5 2009 F1448 F1456
5. H. Kakizawa, M. Itoh, Y. Itoh, S. Imamura, Y. Ishiwata, and T. Matsumoto The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients Metabolism 53 5 2004 550 555
6. D.E. Kohan Biology of endothelin receptors in the collecting duct Kidney Int 76 5 2009 481 486
7. D.E. Kohan Endothelin, hypertension and chronic kidney disease: new insights Curr Opin Nephrol Hypertens 19 2 2010 134 139
8. D.E. Kohan, Y. Pritchett, M. Molitch, S. Wen, T. Garimella, and P. Audhya Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy J Am Soc Nephrol 22 4 2011 763 772
9. D.E. Kohan, N.F. Rossi, E. Inscho, and D. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol Rev 91 1 2011 1 77
10. J.F. Mann, D. Green, K. Jamerson, L. Ruilope, S. Kuranoff, and T. Littke Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 3 2010 527 535
11. A.G. Minchenko, M.J. Stevens, L. White, O. Abatan, K. Komjáti, and P. Pacher Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation FASEB J 17 11 2003 1514 1516
12. M. Morigi, S. Buelli, S. Angioletti, C. Zanchi, L. Longaretti, and C. Zoja In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies Am J Pathol 166 5 2005 1309 1320
13. W. Neuhofer, and D. Pittrow Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence Eur J Clin Invest 39 Suppl. 2 2009 50 67
14. T.J. Opgenorth, A.L. Adler, S. Calzadilla, W. Chiou, B. Dayton, and D. Dixon Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist J Pharmacol Exp Ther 276 2 1996 473 481
15. J. Ortmann, K. Amann, R. Brandes, M. Kretzler, K. Munter, and N. Parekh Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition Hypertension 44 6 2004 974 981